AREDS2 STUDY PDF
Welcome to The Age-Related Eye Disease Study 2 (AREDS2) was a multi-center, randomized trial designed to assess the effects of oral. The Age-Related Eye Disease Study 2 (AREDS2) Research Group* . AREDS2 was designed to test whether adding lutein + zeaxanthin, DHA. Lutein + Zeaxanthin and Omega-3 Fatty Acids for Age-Related Macular Degeneration: The Age-Related Eye Disease Study 2 (AREDS2).
|Published (Last):||7 March 2010|
|PDF File Size:||2.68 Mb|
|ePub File Size:||3.68 Mb|
|Price:||Free* [*Free Regsitration Required]|
The relationship of dietary carotenoid and vitamin A, E, and C intake with age-related macular degeneration in a case-control study: Design Multicenter phase 3 randomized controlled clinical trial.
The impact of fish and shellfish consumption on age-related macular degeneration. The unit of analyses used was by eye. The study enrolled 4, participants aged 50 to 85 years with sufficiently clear media for quality fundus photographs and either: Dietary carotenoids, vitamins A, C, and E, and advanced age-related macular degeneration.
Participants underwent follow-up for a median of 4. In these analyses we assumed that there would be little interaction between the various nutrients tested.
The baseline serum levels of study nutrients were balanced across the treatment groups; the levels xreds2 during the study are reported in eTables The role of omega-3 long-chain polyunsaturated fatty acids in health and disease of the retina. Drs Chew and Clemons had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. These analyses included all the participants randomly assigned to the variations of the AREDS supplement, including smokers.
Invest Ophthalmol Vis Sci.
Age-Related Eye Disease Study 2 (AREDS2) | National Eye Institute
Baseline dietary intake of the study nutrients, including those stud the AREDS supplements, was balanced across treatment groups. Lutein and zeaxanthin and the risk of cataract: Purchase access Subscribe now.
Of the 4, randomized participants, 4, were included for the AMD trial at least one study eye without advanced AMD and 3, were eligible for the cataract studyy phakic in at least one eye. This randomized controlled clinical trial is designed to evaluate the role of macular xanthophylls and omega-3 LCPUFAs on the progression of age-related macular degeneration and, secondarily, progression of cataract.
Oily arfds2 consumption, dietary docosahexaenoic acid and eicosapentaenoic acid intakes, and associations with neovascular age-related macular degeneration. Chemistry and metabolism of sthdy in the vertebrate retina.
Conflict of Interest Disclosures: The use of a self-administered questionnaire to assess diet four years in the past. Another limitation would be our inability to assess the effect of the potential increased risk of lung cancer associated with beta carotene on our analyses of mortality. Masked graders at a central reading center used a standard protocol to assess the photographs. Table 2 reports the distribution of randomization of the variations of the AREDS formulation as well as participants who chose to take the AREDS formulation within each of the treatment groups in the primary randomization.
AREDS2 Results Released | Macular Disease Foundation Australia
Observational data from AREDS, other epidemiologic studies and animal studies, provide a rationale for examining the potential impact of other nutrients on the treatment of AMD. Enrollment was restricted to people between the ages of 50 and 85 years at high risk of progression to advanced AMD with either bilateral large drusen or large drusen in 1 eye and advanced AMD in the fellow eye.
The Author Video Interview is available. The Foundation has been recommending for many years that smokers should not be taking a supplement that included beta-carotene.
Plasma lutein and zeaxanthin and other carotenoids as modifiable risk factors for age-related maculopathy and cataract: Vision Custodian SA Governor: A total of 3, participants agreed to the secondary randomization evaluating different AREDS supplements.
Specifically, the nutritional status of the AREDS2 cohort and the competitive absorption of carotenoids require further assessments.
AREDS2 Results Released
Enrollment was restricted to people determined to be at high risk of progression to advanced AMD with either bilateral large drusen or non-foveal geographic atrophy no advanced AMD or large drusen or non-foveal geographic atrophy in one eye and advanced AMD in the fellow eye AREDS Simple Scale Score of 2, 3 or 4. None of the nutrients affected development of moderate or worse vision loss, defined as a reduction of 15 or more letters from baseline or treatment for neovascular AMD. Likelihood of adherence to the study regimen was evaluated during a run-in phase using study placebo and the AREDS formulation.
The publisher’s final edited version areds this article is available at Ophthalmology. It is not known whether a single specific ingredient is important or if the combination is essential for its therapeutic effect. These null results may be attributable to the true lack of efficacy. The staff of the National Eye Institute and their contractors, led by Dr Chew, had complete control of the design and conduct of the xtudy the collection, management, analysis, and interpretation of the data; and the preparation, review, or approval of the manuscript.
The primary outcome was the development of advanced AMD, defined as central geographic atrophy or retinal features of choroidal neovascularization detected on central grading of the stereoscopic fundus photographs or a history of treatment for advanced AMD after study enrollment. Safety outcomes included serious adverse events and mortality.